BackPhoenix Biotech Acquisition Overview

Phoenix Biotech Acquisition Other Current Liabilities

Phoenix Biotech Acquisition's other current liabilities is $16M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$15.56M
↑ 3206.63% YoYΔ $15.09M vs prior year quarter

Peer trimmed avg / median

Loading

Phoenix Biotech Acquisition Other Current Liabilities History

Loading

Phoenix Biotech Acquisition vs. peers: Other Current Liabilities Comparison

Loading

Phoenix Biotech Acquisition Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Phoenix Biotech Acquisition (PBAX) FAQ

As of the most recent data (June 2026), PBAX shows a other current liabilities of $16M. That compares with $470K in the prior-year period — up 3206.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PBAX's other current liabilities is now $16M (was $470K) — a 3206.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Phoenix Biotech Acquisition is outperforming or lagging.

Tracking PBAX's other current liabilities over time shows whether Phoenix Biotech Acquisition is scaling, shrinking, or reshaping that part of the business. The current reading is $16M That compares with $470K in the prior-year period — up 3206.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Phoenix Biotech Acquisition's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $16M) with ownership activity and broader fundamentals.